Familial hypertrophic cardiomyopathy is a disease caused by mutations in contractile proteins of the sarcomere. Our laboratory developed a mouse model of FHC with a mutation in the thin filament protein -tropomyosin at amino acid 180 (glutamic acid 180 glycine). The hearts of these mice exhibit dramatic systolic and diastolic dysfunction, and their myofilaments demonstrate increased calcium sensitivity. The mice also develop severe cardiac hypertrophy with death ensuing by 6 months. In an attempt to normalize calcium sensitivity in the cardiomyofilaments of the hypertrophic mice, we generated a chimeric -/ -TM protein which decreases calcium sensitivity in transgenic mouse cardiac myofilaments. By mating mice from these two models together, we tested the hypothesis that an attenuation of myofilament calcium sensitivity would modulate the severe physiological and pathological consequences of the familial hypertrophic cardiomyopathy mutation. These double transgenic mice "rescue" the hypertrophic phenotype by exhibiting a normal morphology with no pathological abnormalities.
INTRODUCTION

Familial hypertrophic cardiomyopathy (FHC) is inherited as a Mendelian autosomal
dominant trait and is caused by mutations in any one of ten genes, each encoding protein components of the cardiac sarcomere. Mutations in cardiac -and -myosin heavy chain, myosin binding protein C, cardiac troponin-T, regulatory and essential myosin light chains, titin, -tropomyosin, -actin, and cardiac troponin-I are associated with hypertrophic cardiomyopathy. This genetic diversity is compounded by intragenic heterogeneity with about 200 mutations now identified; most of these are missense mutations with a single amino acid residue substitution (11, 24) . Pathologically, FHC is generally characterized by left ventricular hypertrophy in the absence of an increased external load, myofibrillar disarray, fibrosis, and oftentimes leads to increased calcium (Ca 2+ ) sensitivity of myofilaments.
Eight mutations have been defined in -tropomyosin (TM) that lead to FHC. Four of the mutations occur in the troponin-T binding region (Asp175Asn; Glu180Gly; Glu180Val; Leu185Arg); three mutations lie at the amino end of the TM molecule (Glu62Gln;
Ala63Val; Lys70Thr); and one mutation lies in the middle (Val95Ala) (4, 8, 9, 11, 15) .
To understand the biochemical, morphological and physiological effects of TM mutations in the heart, we developed two transgenic mouse models of FHC with mutations at amino acids 175 (Asp Asn) and 180 (Glu Gly) (14, 21, 22) . Both mutant proteins confer increased Ca 2+ sensitivity to myofilaments and result in decreased myocardial function.
However, the -TM180 mutation causes severe concentric hypertrophy of the heart and the mice die within 6 months of age. Of the eight mutations reported for -TM, at least five of them confer increased Ca 2+ sensitivity to the myofilaments which may be causative for the development of the FHC phenotype (6, 12, 14, 21, 22, 28) . We hypothesized that attenuating the increased Ca 2+ sensitivity of myofilaments by contractile protein modification may prevent the development of FHC and its subsequent lethality. To test this hypothesis, we generated a chimeric -/ -TM transgene ( -/ -TM ( -TM amino acids 1-257 and -TM amino acids 258-284); previous work shows the encoded -/ -TM chimeric protein decreases Ca 2+ sensitivity of myofilaments without altering cardiac morphology in transgenic Chimera 1 mice (7). To examine whether attenuation of increased myofilament Ca 2+ sensitivity may curtail the development of cardiac hypertrophy, we generated double transgenic mice by mating the -TM180 mice with Chimera 1 mice. We obtained the four expected genotypes: non-transgenic (NTG), -TM180, Chimera 1 (Chi 1) transgenic and double transgenic (DTG). While -TM180
and Chimera 1 transgenic mice exhibit their defined phenotypes (7, 21) glycerol) containing 130 mM DTT for 10 minutes, followed by equilibration buffer containing 135 mM Iodoacetamide for another 10 minutes. Strips were then applied to 10% acrylamide gels for SDS-PAGE, followed by transblotting onto PVDF membrane.
Western blot analysis using the striated muscle TM specific CH1 antibody was conducted using a 1:5000 dilution (7). Protein spots that reacted with the TM-specific antibody were quantified by ImageQuant analysis using 3 separate blots for each genotype.
Quantified values were assessed using a Student's t-test, and results are presented as means + S.D.
To quantify the total amount of TM, 5 µg of the myofibrillar fraction from each sample was run on 10% SDS-PAGE gels and were transferred to nitrocellulose filters. Filters were first incubated with striated TM specific CH1 antibody (Sigma), followed by second antibody-HRP conjugate, and the blots were developed using an ECL kit (Pierce). The blots were then stripped of their first and second antibodies using membrane manufacturers instructions. Blots containing the myofibrillar fraction were reacted with sarcomeric anti-actin antibody (clone 5C5 from Sigma) and developed as described earlier. 
Isolated anterograde perfused heart preparation
Control and transgenic mice were anesthetized intraperitoneally with 100 mg/kg sodium nembutal and 1.5U heparin to prevent intracoronary micro thrombi (7). Anterograde work-performing perfusion was initiated at a workload of 250 mmHg mL/min as described (7) . Heart rate (HR), left ventricular pressure (LVP), and the mean coronary perfusion pressure were continuously monitored. The pressure curve was used to calculate the rate of pressure development (+dP/dt) and decline (-dP/dt), time to peak pressure (TPP) and time to half relaxation (RT 1/2 ). Starling curves were generated by linear regression using the software "Origin" [Version 4.0, Microcal TM Software, Inc].
For the regression lines, the average slopes were calculated using only the initial part of the Frank-Starling curve (at cardiac work from 0 to 350 mmHg ml/min). Data is presented as means + S.E.
Skinned fiber bundle preparation and force measurements
Force developed by bundles of detergent-extracted fibers dissected from papillary muscle was measured as previously described (14, 29 
RESULTS
Generation of transgenic mice
The cDNA constructs used to generate the -TM180 and Chimera 1 mice are shown in Figures 1A and 1B mRNA is found only in the DTG and Chimera 1 mice. We hypothesize that the suppression of endogenous -TM mRNA in the TG mice is due to differences in the 5' and 3' UTR sequences; the transgenes incorporate an -MHC 5' UTR and either a HGH or SV40 polyA-3' UTR while may account for the increased transcription, mRNA stability, and/or translation of the transgene transcripts or proteins.
To examine TM protein expression in the control and TG mice, cardiac myofibrillar proteins from all genotypes were subject to two-dimensional gel electrophoresis, followed by immunoblotting with a striated muscle-specific TM antibody. Results show that under reduced conditions, heart myofibrillar protein samples from NTG mice show a single spot, labeled -TM, which is reactive with the TM antibody ( Figure 3A ). In agreement with previous studies on TM composition in cardiac musculature, the results show the -TM isoform is predominant in the heart. Hearts from -TM180 mice express both the endogenous -TM and -TM180 protein isoforms (42.64 + 0.22 % and 57.36 + 0.22 %, respectively), which is in agreement with previous work (22) ( Figure 3B A quantitative analysis was conducted using ImageQuant to determine the amount of TM incorporated into the myofilaments of the TG hearts following Western blot analysis.
The total amount of incorporated striated muscle TM (generated from both endogenous and transgene sources) was normalized to striated muscle actin; the ratio of myofilament TM:actin for NTG hearts was set at 100%. Data show there are no significant differences in the level of total TM incorporation into the myofilaments in the TG hearts: 98.5 + 1.6% for -TM 180 mice; 91.2 + 7.0% for Chimera 1 mice, and 97.9 + 7.1 % for DTG mice. Additional results show there are no changes in the total amount of TM, nor in non-TM cardiac contractile protein expression profiles (including actin) among NTG, -TM 180 mutant, chimera -/ -TM transgenic, and DTG mice (data not shown).
We conducted PCR analyses on TG mouse-tail genomic DNA to negate the possibility that an unexpected mutation or deletion of the -TM180 and or chimeric -/ -TM DNA sequences occurred during transgenesis. PCR fragments were generated using oligonucleotides corresponding to the -MHC and -TM 3'UTR sequences as 5' and 3' primers for Chimera 1 mice, and -MHC and HGH poly A sequences as 5' and 3' primers for -TM180 mice. Nucleotide sequencing of these fragments show there are no mutations or deletions in the incorporated Chimera 1 or -TM180 sequences present in the TG mice.
Histological analysis of DTG mice
Mice from the 4 different genotypes and ranging in age from four months to twelve months were examined for morphological and histological changes. -TM180 mutant mice do display severe morphological and histopathological alterations (21, 22) ; at 4 months, these mice display severe hypertrophy, fibrosis, enlarged left atria and calcification of left atria. On a gross level, there are no obvious morphological differences in 4-or 6-month or 1 year-old NTG, DTG, or Chimera 1 mouse hearts ( Figure 4A and B). Histochemical analyses of the heart sections show no signs of cardiac hypertrophy, fibrosis, thrombi, necrosis or any other pathological condition in NTG, Chimera 1, and DTG mice. Also, there are no differences in percent heart/body weight ratios among these three genotypes (Table 1) . These results show that incorporation of chimeric -/ -TM protein into the DTG myofibers, which also contain the -TM180 protein, prevents the development of hypertrophy and severe pathological alterations.
This attenuation of cardiac hypertrophy and fibrosis lasts at least 1 year.
Physiological analyses of the DTG mice
We pursued several lines of experiments to address cardiac muscle performance in DTG
mice. An isolated anterograde perfused heart preparation was employed to carry out a functional analysis of hearts from the four genotypes at 4 months of age and three genotypes (NTG, Chimera 1, and DTG) at 12 months of age. Previous work using echocardiography and the isolated work-performing heart method show that at 2.5 -3 months of age, the -TM180 hearts exhibit normal heart rates (22); by 4 months of age, these hearts are severely stressed (Table 1) . At 4 months, Chimera 1 and -TM180
hearts produce systolic pressures that are significantly lower than the control hearts, but the DTG hearts have a similar level of systolic pressure compared to the NTG controls (Table 1 ). The maximal rate of pressure development for contraction (+dP/dt) is significantly decreased in the Chimera 1 and -TM180 hearts, but DTG hearts display similar rates as NTG. The time to peak pressure (TPP) is faster in control and DTG hearts than in either the Chimera 1 or -TM180 hearts ( Table 1 ). The maximal rate of pressure decline (-dP/dt) is also decreased in all TG groups; however, half time to relaxation (RT½) is only increased in -TM180 hearts.
To determine whether the improved phenotype of the DTG mice would persist for greater than 4 months, we aged the mice and performed the isolated work performing analysis on one-year-old hearts ( -TM180 mice do not survive beyond 6 months). Results show there were no differences between the NTG and DTG hearts for the heart weight:body weight ratio, intrinsic heart rates or systolic parameters in one-year-old mice (Table 2) .
However, hearts from DTG and Chimera 1 mice exhibit several altered cardiac parameters, including increased diastolic and end diastolic pressures and a prolongation of RT½, possibly indicative of impending cardiac disease and failure. Previous studies
show that over expression of wild type -TM in transgenic mice does not lead to alterations in morphology or physiological performance of the heart (21, 29).
Response to change in workload
The Frank-Starling relationship reflects the increase in cardiac performance in response to increased intraventricular pressure or volume load. To determine to what extent the DTG mice could be loaded with increasing workload, cardiac minute work was varied from 50 mm Hg ml/min to the maximal level of mean aortic pressure (afterload) that can be generated at a given venous return (preload) of 5 ml/min. The hearts from all 4 groups are sensitive to increases in afterload for +dP/dt at 4 months of age ( Figure 5A ).
However, there is no increased response for -dP/dt (diastolic state) in the -TM180 mice at this age, most likely due to the severe pathological condition of the hearts at this time.
Also, there are no significant differences in the responses between the NTG and DTG hearts to increased workload at 4 months. By one year, the plots of cardiac work versus the rates of pressure development (+dP/dt) demonstrate an overall reduction for the Chimera 1 mice, with no significant differences between the NTG and DTG mice ( Figure 5B ). There is, however, a diminished response in the DTG from the NTG at one year in the diastolic state (-dP/dt), where the y-intercept is significantly lower for the DTG and Chimera 1 mice than for the NTG. The slopes of the regression curves for the DTG at one year are not different, indicating that the maximal -dP/dt and +dP/dt were sensitive to length-dependent regulation to an extent similar to that in the NTG hearts.
Response to -adrenergic stimulation
We examined the effect of isoproterenol in working hearts to evaluate the possible 
Ca
2+ -force measurements in skinned fiber bundles
To examine the correlation between physiological results from the whole heart and transgene expression at the sarcomere level, experiments were conducted using detergent-extracted (skinned) fiber bundles. Figure 7 shows data comparing pCa-% maximum force relations obtained from NTG, Chimera 1, -TM180, and DTG hearts.
Parameters describing these relations are summarized in ] required for half-maximum activation) are similar between NTG and DTG fiber bundles at both sarcomeric lengths (Table 3 , Figure   7A and B). However, there are significant differences between NTG and -TM180 myofilaments, which exhibit an increased sensitivity to Ca 2+ at both 1.9 and 2.3 µm lengths, and Chimera 1 myofilaments that exhibit a decreased sensitivity to Ca 2+ . These results clearly show that incorporation of Chimera 1 protein into myofilaments containing -TM180 protein attenuates the effect of -TM180 mutation on myofilament Ca 2+ sensitivity at both sarcomeric lengths.
We also determined Hill n values as a measure of cooperative Ca 2+ -activation of the myofilaments from hearts of the 4 distinct genotypes. Within each genotype, the Hill values appear constant and independent of sarcomere length (Table 3) . Interestingly, there is a decrease in cooperativity in the DTG myofilaments associated with increased sarcomere length. Significant differences in Hill values were observed between -TM180 and Chimera 1 myofilaments at both sarcomeric lengths. There was also a significant difference between Chimera 1 Hill values and those of the DTG at 1.9 µm.
DISCUSSION
Numerous studies demonstrate that aberrant Ca 2+ levels in the cardiomyocyte can lead to severe pathological consequences, including hypertrophy and heart failure (5, 31 changes in TM expression, and why is the Chimera 1 TM molecule able to "rescue" the hypertrophic phenotype in the FHC -TM180 mouse? We assume cardiac muscle functions as an integrated whole in determining sarcomeric tension and relaxation;
whether this occurs through the summation of small individual regions that preferentially incorporate a specific TM protein or is a total unit of random TM protein integration is
unknown. An area of future investigation is to determine whether there is preferential TM dimer formation of the endogenous -TM with either -TM180 or Chimera 1 proteins, and whether -TM180 and Chimera 1 protein preferentially dimerize.
Regardless, increased Ca 2+ sensitivity and its effect on myofilament function appear to play a critical role in the development of pathological hypertrophy, and modulation of Ca 2+ sensitivity through various pathways may prove to be a viable approach for treatment of cardiovascular disease (25). Realtime RT-PCR analysis was conducted on NTG and TG cardiac RNA using primers specific for endogenous -TM, -TM180, or Chimera 1 TM mRNAs. Values were normalized to GAPDH levels. Table 3 for a summary of parameters describing the pCa-force relations. Table 2 Parameters describing cardiac function at 1 year in NTG and TG hearts 4.5 ± 0.82** -5.9 ± 3.5 -4.5 ± 1. Body weight (g) 34.8 ± 3.1 29.9 ± 5.3 34.9 ± 8.4 Table 3 Parameters describing Ca
2+
-dependent activation of tension in skinned fiber bundles from NTG and TG hearts 
